METOCLOPRAMIDE IN TARDIVE DYSKINESIA by Hemanani, T.J. et al.
Indian J. Psychiat. (1983), 25(2), 134—137 
METOCLOPRAMIDE IN TARDIVE DYSKINESIA 
T.J.HEMNANI
1, M.D. (Pharmacology), D.R.M. 
P.G. DASHPUTRA», M.D. (Pharmacology) 
R.N. SARDA", M.D. (Psychiatry), D.P.M. 
SUMMARY 
The effect ofsingle intravenous doses of metoclopramide (10 mg, 20 mg and 40 mg) have been com-
pared with placebo (saline) in a double blind randomised study in 10 patients with tardive dyskinesia follow-
ing long term neuroleptic therapy. Tardive dyikinesia rating scores were decreased significantly (P<0.01) 
6 hours after administration of metoclopramide 20 mg and 40 mg when compared with placebo. Reduction 
of tardive dyskinesia by metoclopramide-a D, receptor blocking agent suggest that D, receptors may be in-
volved in the mediation of this syndrome. 
Tardive dyskinesia is an abnormal 
movement disorder involving predomi-
nantly buccolii guomasticatory muscles in 
patients receiving neuroleptic therapy on 
a long term basis. The movements are 
diminished if the dose of neuroleptic drug 
is increased (Kobayashi, 1977), and the 
disorder may be due to increased dopa-
minergic activity within the central ner-
vous system, occurring as a result of chronic 
dopamine receptor blockade (Klawans, 
1973). 
Drugs of varying groups have been 
tried in the treatment of tardive dyskinesia 
(Mackay and Sheppard, 1979) hypothe-
sising various etiological factors (Gardos 
et al., 1977). There is some evidence from 
animal studies that Ds receptors may 
mediate peri-oral dyskinesias in guinea 
pigs (Costall and Naylor, 1978). There-
fore now a days interest is bek g focussed 
on the use of drugs which specifically 
block Da receptor sites e. g. pimozide and 
the substituted benzamides like oxipero-
mide, tiapride and metoclopramide (Keba-
bian and Calne, 1979). Of these drugs 
only pimozide has been studied in tar-
dive dyskinesia (Claveria et al., 1975). 
However, in the treatment of L-dopa 
induced dyskinesia both oxiperomide 
(Bedard et al., 1978) and tiapride (Lees 
et al., 1979) have been reported to be of 
value but metoclopramide (Tarsy et al., 
1975) seemed to be ineffective. We have 
therefore tried to investigate the potential 
of metoclopramide in the treatment of 
tardive dyskinesia following long term 
neuroleptic therapy. 
MATERIAL AND METHOD 
An informed consent of the patients 
and next of kin was obtained. Ten 
patients (sev n women and three men) 
diagnosed as tardive dyskinesia by two 
psychiatrists independently were taken up 
for study. All medications were stopped 
for 1 month prior to study. The patients 
selected were between the age range of 
35 and 50 years. 
The study was double blind and the 
order of drug administration was rando-
mized for each patient. Patients were 
given, in random order, single intrave-
nous injections of either placebo (saline) 
or metoclopramide (10 mg, 20 mg or 40 
mg) between 9.30 and 10.00 A. M. on 
the study days. Every patients received 
all four treatments at an interval of 7 
days between treatments. Patients were 
assessed for dyskinetic movements, using 
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TABLE 1. The NIM dyskinesia score: Each 
feature is scored from 0 {norma') 
to 4 {Maximal abnormality). 
Score 
1. Facial and Oral Movements 
Muscles of fjcial expression 
Lips and peri-ora 1 area 
Jaw 
Tongue 
2. Exteremity Movements 
Upper Limbs 
Lower Limbs 
3. Trunk Movements 
IS'eck, shoulder and hips 
4. Restlessness 
0—4 
0—4 
0—4 
0—4 
0—4 
0-4 
0—4 
0—4 
the first seven items on the NIMH scale 
(NIMH Psychopharmacology Research 
Branch, 1975) (Table-1). Abnormal move-
ments were scored on the scale imme-
diately before the iijections and at 1, 3 
and 6 hours afterwards by two psychiat-
rists. 
The individual scores for the various 
dyskinetic movements were summed ('sum 
dyskinesia score') and the results were 
analysed to find out mean and standard 
error of mean for each group-and the 
statistical significance was found out using 
two tailed student's 't' test. 
RESULTS 
There was a significant (p<0.01) 
reduction in the sum dyskinesia score at 
1, 3 and 6 hours with all treatments ex-
cept metoclopramide (10 mg) and place-
bo (Table 2) 
TABLE 2. Sum dyskinesia score before and after treatment with metoclopramide. 
DRUGS 
Saline (placebo) 
Metoclopramide 10 mg 
Metoclopramide 20 mg 
Metoclopramide 40 mg 
Score (meanJ^S.E.M.) 
Before treatment 
19.6±1.1 
19.5±l.l 
19.1±1.0 
19.4±0.9 
lh 
18.3i;0.9 
I8.5±l.l 
15.1±0.9* 
13.4-J-0.7* 
After treatment); 
3h 
17.3±1.0 
17.7±1.1 
11.9±0.6* 
10.6±0.6» 
6h 
17.2±0.9 
17.5±1.0 
11.2±0.7» 
8.7±0.5» 
@ value was compared with score before treatment 
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DISCUSSION 
Effective treatment of tardive dyski-
nesia has not yet been achieved. So far 
only treatment of tardive dyskinesia has 
been the omission of neuroleptic drug, 
though increase in the dose of neuroleptic 
drug results in temporary cessation of 
dyskinetic movements (Inoue, 1979). 
The present study was designed to 
assess the potential of metoclopramide in 
the control of tardive dyskinesia. We 
have seen that metoclopramide decreases 
dyskinetic movements after single intrave-
nous i jection (20 and 40 mg). Oxipero-
mide and tiapride—the other representa-
tives of substituted benzamide compounds 
have been found to be effective in I-dopa 
induced dyskinesia (Bedard et al., 1978; 
Lees et al., 1979) and it has been suggested 
that this antidyskinetic action is mediated 
through D2 receptor blockade. We there-
fore suggest that the antidyskinetic ac-
tion of metoclopramide is also mediated 
through blockade of D2 receptors since it 
bears structural resemblance to oxipero-
mide and tiapride. 
The maximum clinical antidyskinetic 
action was observed at 6 hours interval 
after administration of the drug though 
C. N. S. effects of metoclopramide occur 
within 15 minutes of intravenous adminis-
tration (Batesman et al, 1978). We 
have no explanation for this delayed anti-
dyskinetic action of metoclopramide which 
needs further research. 
Metoclopramide itself has been 
reported to produce tardive dyskinesia 
(Lavy et al., 1978). In this respect it 
resemble neuroleptic compounds though 
metoclopramide does not possess neuro-
leptic action in human beings (Nakra et al., 
1975). However, in animals metoclopra-
mide has been shown to have an anti-
psychotic action when used in combination 
with tolazoline, propranolol, phenobar-
bitone, phenytoin or mepyramine (Hem-
nani and Dashputra, 1982). 
Our studies suggest that stimulation 
of D, receptors is, at least in part, respon-
sible for tardive dyskinesia as it is alleviated 
by metoclopramide which is a selective 
D2 receptor blocking agent. The effect 
of long term metoclopramide therapy on 
tardive dyskinesia has been undertaken 
by us to explore whether the danger of 
breakthrough supersensitivity exist with 
metoclopramide as with neuroleptic drugs. 
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